摘要
代谢功能障碍相关脂肪性肝病(MASLD)是巨大的公共卫生问题,严重影响人类的健康,目前针对MASLD新药研发取得了一些不错的进展,但仍有极大的探索空间。现总结目前针对MASLD新药研发的临床现状与面临的挑战,并对原因进行分析。
Metabolic dysfunction-associated fatty liver disease(MASLD)is a major public health problem that seriously affects human health.At present,some good progress has been made in the research and development of new drugs for MASLD,but there is still great space for exploration.This paper summarizes and analyzes the reasons in the current clinical status and challenges for the research and development of new drugs for MASLD.
作者
罗听
陆伦根
茅益民
Luo Xin;Lu Lungen;Mao Yimin(Department of Gastroenterology,Shanghai General Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200080,China;Department of Gastroenterology,Shanghai Renji Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200001,China)
出处
《中华肝脏病杂志》
CAS
CSCD
北大核心
2024年第4期300-302,共3页
Chinese Journal of Hepatology
基金
国家重点研发计划(2022YFC3502101)
国家科技部十三五科技重大专项(2017ZX09304016)
国家自然科学基金(81970513、82270619)。
关键词
脂肪肝
代谢功能障碍相关脂肪性肝病
药物靶点
临床试验
研究进展
Fatty liver
Metabolic dysfunction associated fatty liver disease(MASLD)
Drug targets
Clinical trials
Research progress
